AUTHOR=Al-Moraissi Essam Ahmed , Al-Zendani Elham Aziz , Al-Selwi Abeer Mohammed 

TITLE=Efficacy of Submucosal Injection of Chymotrypsin, Oral Serratiopeptidase or Oral Dexamethasone in Reducing Postoperative Complications Following Impacted Lower Third Molar Surgery: A Prospective, Randomized, Double-Blind, Controlled Clinical Trial

JOURNAL=Frontiers in Oral Health

VOLUME=Volume 1 - 2020

YEAR=2020

URL=https://www.frontiersin.org/journals/oral-health/articles/10.3389/froh.2020.575176

DOI=10.3389/froh.2020.575176

ISSN=2673-4842

ABSTRACT=Aim: the study aimed to compare between chymotrypsin, oral serratiopeptidase and oral dexamethasone following impacted mandibular third molars surgery in respect of postoperative complications.
Materials and method: A randomized, double-blinded, clinical trial was conducted on 60 patients who were the candidate to impacted mandibular third molars surgery and randomly allocated into the following 3 groups: submucosal chymotrypsin (5 mg), oral serratiopeptidase (10mg) and oral dexamethasone (8mg) (each group = 20). The outcomes variables were postoperative pain ( via visual analogue scale), facial swelling (via tape method) and maximal mouth opening immediately after the procedure, 2nd day, 3rd day and 5th day after the surgery.
Results: A total of sixty patients underwent randomization and allocation concealment and were included in the current study. All of the subjects tolerated the medicines with no untoward side or adverse effects.
There was no statistically significant difference between the three groups in respect of postoperative pain intensity , facial swelling and maximal mouth opening at the immediate first hour, 2nd, 3rd and fifth days (P < 0.05). 
Conclusion: the present randomized clinical trial concluded that  preemptive sub-mucosal injection of chymotrypsin yield a comparable effectiveness in decreasing postoperative sequelae following impacted mandibular third molars surgery when compared to oral serratiopeptidase and corticosteroids. This is a first Randomized Clinical Trail that assessed efficacy and safety of sub-mucosal injection of chymotrypsin after impacted mandibular third molars surgery.